We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Antibiotics for Diarrhea Increase Risk of Superbug Colonization

By HospiMedica International staff writers
Posted on 01 Feb 2015
A new study warns that treating travelers' diarrhea (TD) with antibiotics turns them into unknowing carriers of drug-resistant bacteria, and may even contribute to the spreading of these superbugs in their native countries.

Researchers at Helsinki University Hospital (Finland) collected stool samples from 430 Finns before and after traveling outside of Scandinavia. More...
All the specimens were analyzed for Extended-Spectrum Betalactamase-Producing Enterobacteriaceae (ESBL, an enzyme that shields the superbugs against common antibiotics) and carbapenemase-producing Enterobacteriaceae (CPE). Questionnaires were used to survey the participants about use of antimicrobials during their trip, as well as other potential risk factors.

The results revealed that 21% of the travelers had become colonized by ESBL-PE, but none by CPE. Geographic region, occurrence of TD, age, and use of antibiotics were identified as independent risk factors predisposing to contracting ESBL-PE, with nearly 40% of the travelers colonized with ESBL-producing bacteria. However, those who took antibiotics for TD while visiting South-Asian countries, such as India, Bangladesh, and Pakistan, faced the highest risk, with nearly 80% colonized by ESBL-PE. The study was published on January 21, 2015, in Clinical Infectious Diseases.

“The great majority of all cases of travelers’ diarrhea are mild and resolve on their own,” concluded lead author, Professor of Epidemics, Anu Kantele, MD, and colleagues. “In modern pre-travel counseling for those visiting high-risk regions, travelers should be advised against taking antibiotics for mild or moderate travelers' diarrhea.”

TD affects 20%–50% of international travelers (an estimated 10 million persons annually), with the primary source being ingestion of unhygienic, fecally contaminated food or water. The onset of TD usually occurs within the first week of travel but may occur at any time while traveling, and even after returning home. The most important determinant of risk is the traveler's destination; high-risk destinations are the developing countries of Latin America, Africa, the Middle East, and Asia. Persons at particular high-risk include young adults, the immunosuppressed, people with inflammatory-bowel disease or diabetes, and those taking H-2 blockers or antacids.

Related Links:

Helsinki University Hospital



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.